Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNKT Cells + TAE/TACE for Unresectable HCC
NCT04011033Phase 2Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Mar 2018; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04011033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011033.